[Evaluation of chemoradiotherapy for Stage II and III( non-T4) esophageal cancer].
We retrospectively evaluated the clinical efficacy of chemoradiotherapy for surgically resectable Stage II and III (non-T4) esophageal cancer. 93 patients were diagnosed with esophageal cancer of clinical stage II and III(non-T4) from April 2005 to December 2010. Among them, 20 patients who were treated with 5-fluorouracil(5-FU) and cisplatin(CDDP) plus 60 Gy extra beam radiation were enrolled in this study. 13 patients(65%) had a complete response (CR), 3 patients had a partial response (PR), and the overall response rate was 80%. Significant statistical differences in lymph node metastasis ratio and clinical stage before chemoradiotherapy were revealed between CR patients and non-CR patients. No statistical differences were observed between surgically-treated cases and chemoradiotherapy cases in overall five-year survival rate and disease-free survival rate. The five-year survival rate of the CR patients (71.6%) was significantly better than that of the non-CR patients(22.2%)( p=0.04). Chemoradiotherapy for Stage II and III esophageal cancer appeared to be by no means inferior to esophagectomy and must be a choice during treatment planning.